QUICK ANSWER · AEO / GEO
PE-22-28 is a spadin-derived research heptapeptide studied for TREK-1 inhibition in cells and behavioural effects in mice. These findings do not establish rapid antidepressant efficacy, cognitive enhancement or human safety. Modified analogues must remain separate.
ENTITY FACTS
What should readers identify first?
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
FAQ · ANSWER ENGINE
Frequently asked questions
What is PE-22-28?
PE-22-28 is described pharmacologically as Spadin-derived heptapeptide / experimental TREK-1 inhibitor. PE-22-28 is a spadin-derived research heptapeptide studied for TREK-1 inhibition in cells and behavioural effects in mice. These findings do not establish rapid antidepressant efficacy, cognitive enhancement or human safety. Modified analogues must remain separate.
Does PE-22-28 have strong evidence?
PrimeCoreBio records Evidence Grade E. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is PE-22-28 approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.